Sweden-based Cantargia has awarded a contract to BioInvent International for manufacturing CAN10, a monoclonal antibody which is in preclinical development for the treatment of systemic sclerosis and myocarditis.
CAN10, which is a fully humanized monoclonal antibody, targets IL1RAP.
The monoclonal antibody has been designed to inhibit the signalling of the inflammatory cytokines IL-1, IL-33, and IL-36, which is said to result in unique properties for treatment of inflammatory diseases.
As per the agreement, BioInvent could generate revenue of up to SEK 30 million from the manufacturing contract.
The Swedish company will be responsible for process development, scale-up, supply of material for toxicological studies and also clinical grade material in 1000L scale for use in phase 1 and 2 clinical trials.
Göran Forsberg – CEO at Cantargia said: “We are very excited to start working with BioInvent to advance our CAN10 program towards clinical trials as quickly as possible. Based on Bioinvent’s deep antibody knowledge and recent investments in manufacturing capabilities, we are confident in efficient and timely manufacturing of CAN10.”
The majority of the manufacturing work will be wrapped up next year to begin clinical trials as soon as possible during 2022.
Cantargia, which is engaged in developing antibody-based therapeutics for various forms of cancer and inflammatory diseases, is BioInvent’s new manufacturing customer.
Martin Welschof – CEO of BioInvent said: “We are pleased to add Cantargia to our growing list of manufacturing customers, which is a clear testament to our expertise in state-of-the-art antibody manufacturing and the quality of our processes.”